Needham analyst Mike Matson reiterated a Hold rating on ResMed (NYSE: RMD).The analyst commented: "RMD's F2Q25 revenue and EPS beat ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE